Skip to main content

Biomarkers in the Management of Heart Failure

Current Treatment Options in Cardiovascular Medicine volume 12, pages 519–531 (2010)Cite this article

Opinion statement

Biomarkers, especially natriuretic peptides such as B-type natriuretic peptide (BNP) and N-terminal-proBNP (NT-proBNP), are a valuable addition to standard clinical assessment in the diagnosis and prognosis of heart failure (HF). Furthermore, there is an increasing amount of evidence suggesting that natriuretic peptide–guided HF management may improve mortality, morbidity, and cost effectiveness. This work focuses on the use of BNP or NT-proBNP for the outpatient management of patients with chronic HF.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Figure 1

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Singh V, Martinezclark P, Pascual M, et al.: Cardiac biomarkers—the old and the new: a review. Coron Artery Dis 2010, 21:244–256.

    Article  PubMed  Google Scholar 

  2. Braunwald E: Biomarkers in heart failure. N Engl J Med 2008, 358:2148–2159.

    CAS  Article  PubMed  Google Scholar 

  3. Mann DL: Pathophysiology of heart failure. In Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 8. By Libby P, Bonow RO, Mann DL, Zipes DP. Philadelphia: WB Saunders; 2007:546.

    Google Scholar 

  4. Piao FL, Park SH, Han JH, et al.: Dendroaspis natriuretic peptide and its functions in pig ovarian granulosa cells. Regul Pept 2004, 118:193–198.

    CAS  Article  PubMed  Google Scholar 

  5. Omland T, Hagve TA: Natriuretic peptides: physiologic and analytic considerations. Heart Fail Clin 2009, 5:471–487.

    Article  PubMed  Google Scholar 

  6. Rubattu S, Sciarretta S, Morriello A, et al.: NPR-C: a component of the natriuretic peptide family with implications in human diseases. J Mol Med 2010 (in press).

  7. Richards M, Troughton RW: NT-proBNP in heart failure: therapy decisions and monitoring. Eur J Heart Fail 2004, 6:351–354.

    CAS  Article  PubMed  Google Scholar 

  8. van Kimmenade RR, Januzzi Jr JL, Bakker JA, et al.: Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol 2009, 53:884–890.

    Article  PubMed  Google Scholar 

  9. Maisel AS, Krishnaswamy P, Nowak RM, et al.: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161–167.

    CAS  Article  PubMed  Google Scholar 

  10. Januzzi JJL, Camargo CA, Anwaruddin S, et al.: The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency department (PRIDE) study. Am J Cardiol 2005, 95:948–954.

    CAS  Article  PubMed  Google Scholar 

  11. Doust JA, Pietrzak E, Dobson A, et al.: How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005, 330:625.

    CAS  Article  PubMed  Google Scholar 

  12. Michihiro Y, Yuji M, Masafumi N, et al.: B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Am J Med 2002, 112:716–720.

    Article  Google Scholar 

  13. Latini R, Masson S, Anand I, et al.: Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002, 106:2454–2458.

    CAS  Article  PubMed  Google Scholar 

  14. Stanek B, Frey B, Hülsmann M, et al.: Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001, 38:436–442.

    CAS  Article  PubMed  Google Scholar 

  15. Jeffrey WH, Cheuk MY, Gabriel Y, et al.: Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 2003, 92:406–410.

    Article  Google Scholar 

  16. Berry C, Murphy N, De Vito G, et al.: Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. Eur J Heart Failure 2007, 9:429–434.

    CAS  Article  Google Scholar 

  17. Menardi E, Vado A, Rossetti G, et al.: Cardiac resynchronization therapy modifies the neurohormonal profile, hemodynamic and functional capacity in heart failure patients. Arch Med Res 2008, 39:702–708.

    CAS  Article  PubMed  Google Scholar 

  18. Fruhwald FM, Fahrleitner-Pammer A, Berger R, et al.: Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J 2007, 28:1592–1597.

    CAS  Article  PubMed  Google Scholar 

  19. Ryder M, Murphy NF, McCaffrey D, et al.: Outpatient intravenous diuretic therapy; potential for marked reduction in hospitalisations for acute decompensated heart failure. Eur J Heart Failure 2008, 10:267–272.

    Article  Google Scholar 

  20. Maeda K, Tsutamoto T, Wada A, et al.: High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiology 2000, 36:1587–1593.

    CAS  Article  Google Scholar 

  21. Shah RV, Januzzi Jr JL: ST2: a novel remodeling biomarker in acute and chronic heart failure. Curr Heart Fail Rep 2010, 7:9–14.

    CAS  Article  PubMed  Google Scholar 

  22. Bhardwaj A, Januzzi Jr JL: ST2: a novel biomarker for heart failure. Expert Rev Mol Diagn 2010, 10:459–464.

    CAS  Article  PubMed  Google Scholar 

  23. Masson S, Latini R, Anand IS, et al.: Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006, 52:1528–1538.

    CAS  Article  PubMed  Google Scholar 

  24. Januzzi Jr JL, Sakhuja R, O’Donoghue M, et al.: Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 2006, 166:315–320.

    CAS  Article  PubMed  Google Scholar 

  25. Pascual-Figal DA, Domingo M, Casas T, et al.: Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. Eur Heart J 2008, 29:1011–1018.

    CAS  Article  PubMed  Google Scholar 

  26. Wu AH: Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 2006, 152:828–834.

    CAS  Article  PubMed  Google Scholar 

  27. Schou M, Gustafsson F, Nielsen PH, et al.: Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail 2007, 9:68–74.

    CAS  Article  PubMed  Google Scholar 

  28. José Paulo A, Ana A, Patrícia L, et al.: Intraindividual variation of amino-terminal pro-B-type natriuretic peptide levels in patients with stable heart failure. Am J Cardiol 2006, 98:1248–1250.

    Article  Google Scholar 

  29. Shah MR: Abstract 2554: STARBRITE: a randomized pilot trial of bnp-guided therapy in patients with advanced heart failure. Circulation 2006, 114(18_MeetingAbstracts):II_528.

    Google Scholar 

  30. Jourdain P, Jondeau G, Funck F, et al.: Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007, 49:1733–1739.

    CAS  Article  PubMed  Google Scholar 

  31. Pfisterer M, Buser P, Rickli H, et al.: BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009, 301:383–392.

    CAS  Article  PubMed  Google Scholar 

  32. Lainchbury JG, Troughton RW, Strangman KM, et al.: N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2009, 55:53–60.

    Article  PubMed  Google Scholar 

  33. Cleland JG, Coletta AP, Clark AL, et al.: Clinical trials update from the American College of Cardiology 2009: ADMIRE-HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIX-HF-5, vagal stimulation, REVIVAL-3, pre-RELAX-AHF, ACTIVE-A, HF-ACTION, JUPITER, AURORA, and OMEGA. Eur J Heart Fail 2009, 11:622–630.

    Article  PubMed  Google Scholar 

  34. Berger R, Moertl D, Peter S, et al.: N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 2010, 55:645–653.

    CAS  Article  PubMed  Google Scholar 

  35. Felker GM, Hasselblad V, Hernandez AF, et al.: Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009, 158:422–430.

    CAS  Article  PubMed  Google Scholar 

  36. Porapakkham P, Zimmet H, Billah B, et al.: B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 2010, 170:507–514.

    CAS  Article  PubMed  Google Scholar 

  37. Schou M, Gustafsson F, Videbaek L, et al.: Design and methodology of the NorthStar Study: NT-proBNP stratified follow-up in outpatient heart failure clinics—a randomized Danish multicenter study. Am Heart J 2008, 156:649–655.

    CAS  Article  PubMed  Google Scholar 

  38. Bhardwaj A, Rehman SU, Mohammed A, et al.: Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. Am Heart J 2010, 159:532–538 e1.

    CAS  Article  PubMed  Google Scholar 

  39. ClinicalTrials.gov: Improvement of Patients With Chronic Heart Failure Using NT-proBNP (EXIMPROVECHF). Available at http://www.clinicaltrials.gov/ct2/show/NCT00601679?term=NT-probnp&rank=1. Accessed June 3, 2010.

  40. ClinicalTrials.gov: Evaluation of Heart Failure Treatment Guided by NTproBNP vs Clinical Symptoms and Signs Alone. Available at http://www.clinicaltrials.gov/ct2/show/NCT00391846?term=Persson&rank=4. Accessed June 3, 2010.

  41. Members WC, Hunt SA, Abraham WT, et al.: Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation 2009, 2009(119):e391–479.

    Google Scholar 

  42. Heart Failure Society of America: Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Cardiac Failure 2010, 16:475–539.

    Article  Google Scholar 

  43. Cohn JN, Tam SW, Anand IS, et al.: Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. J Card Fail 2007, 13:331–339.

    CAS  Article  PubMed  Google Scholar 

  44. Marcus LS, Hart D, Packer M, et al.: Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996, 94:3184–3189.

    CAS  PubMed  Google Scholar 

  45. Heublein DM, Huntley BK, Boerrigter G, et al.: Immunoreactivity and guanosine 3′, 5′-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 2007, 49:1114–1149.

    CAS  Article  PubMed  Google Scholar 

  46. Manginas A, Tsiavou A, Sfyrakis P, et al.: Increased number of circulating progenitor cells after implantation of ventricular assist devices. J Heart Lung Transplant 2009, 28:710–717.

    Article  PubMed  Google Scholar 

Download references

Disclosure

James L. Januzzi has received significant grant support from Roche Diagnostics, Siemens, and Critical Diagnostics.

Han-Na Kim has no potential conflicts of interest relevant to this article.

Author information

Affiliations

  1. Cardiology Division, Massachusetts General Hospital, 32 Fruit Street, Yawkey 5984, Boston, MA, 02114, USA

    Han-Na Kim MD, MPH & James L. Januzzi Jr. MD

Authors
  1. Han-Na Kim MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James L. Januzzi Jr. MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James L. Januzzi Jr. MD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kim, HN., Januzzi, J.L. Biomarkers in the Management of Heart Failure. Curr Treat Options Cardio Med 12, 519–531 (2010). https://doi.org/10.1007/s11936-010-0096-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-010-0096-3

Keywords

  • Heart Failure
  • Natriuretic Peptide
  • Heart Failure Patient
  • Systolic Heart Failure
  • Heart Failure Therapy